Tags

Type your tag names separated by a space and hit enter

Paliperidone ER versus risperidone for neurocognitive function in patients with schizophrenia: a randomized, open-label, controlled trial.
Int Clin Psychopharmacol. 2012 Sep; 27(5):267-74.IC

Abstract

This study aims to determine the effectiveness of paliperidone extended release (ER) on cognitive function in patients with schizophrenia in comparison with risperidone. This was a 12-week, randomized, open-label study on schizophrenia patients who were receiving risperidone. The patients were randomized to a risperidone-continuation group or a paliperidone-switch group. The primary outcome measure was neurocognitive function, which was measured using a computerized battery. Secondary efficacy measures included the Positive and Negative Syndrome Scale, Social and Occupational Functioning Scale, and Calgary Depression Scale for Schizophrenia. In total, 58 patients participated in this trial. Improvements in recall after an interference phase in the verbal learning test were significantly greater in the paliperidone-switch than in the risperidone-continuation group. No significant differences in changes were observed in the other six neurocognitive domains measured. Improvements in the Social and Occupational Functioning Scale were significantly greater in the paliperidone ER-switch group than in the risperidone-continuation group. In other efficacy outcome measures, no significant differences were observed between the two drugs. Paliperidone ER had a side-effect profile similar to that of risperidone, including metabolic problems and prolactin-related adverse events. In conclusion, switching from risperidone to paliperidone ER may lead to additional cognitive and social functional improvements.

Authors+Show Affiliations

Department of Psychiatry, Chonnam National University Medical School, Jeonju, Republic of Korea.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

22809972

Citation

Kim, Sung-Wan, et al. "Paliperidone ER Versus Risperidone for Neurocognitive Function in Patients With Schizophrenia: a Randomized, Open-label, Controlled Trial." International Clinical Psychopharmacology, vol. 27, no. 5, 2012, pp. 267-74.
Kim SW, Chung YC, Lee YH, et al. Paliperidone ER versus risperidone for neurocognitive function in patients with schizophrenia: a randomized, open-label, controlled trial. Int Clin Psychopharmacol. 2012;27(5):267-74.
Kim, S. W., Chung, Y. C., Lee, Y. H., Lee, J. H., Kim, S. Y., Bae, K. Y., Kim, J. M., Shin, I. S., & Yoon, J. S. (2012). Paliperidone ER versus risperidone for neurocognitive function in patients with schizophrenia: a randomized, open-label, controlled trial. International Clinical Psychopharmacology, 27(5), 267-74. https://doi.org/10.1097/YIC.0b013e328356acad
Kim SW, et al. Paliperidone ER Versus Risperidone for Neurocognitive Function in Patients With Schizophrenia: a Randomized, Open-label, Controlled Trial. Int Clin Psychopharmacol. 2012;27(5):267-74. PubMed PMID: 22809972.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Paliperidone ER versus risperidone for neurocognitive function in patients with schizophrenia: a randomized, open-label, controlled trial. AU - Kim,Sung-Wan, AU - Chung,Young-Chul, AU - Lee,Yo-Han, AU - Lee,Jeong-Hoon, AU - Kim,Seon-Young, AU - Bae,Kyung-Yeol, AU - Kim,Jae-Min, AU - Shin,Il-Seon, AU - Yoon,Jin-Sang, PY - 2012/7/20/entrez PY - 2012/7/20/pubmed PY - 2013/1/10/medline SP - 267 EP - 74 JF - International clinical psychopharmacology JO - Int Clin Psychopharmacol VL - 27 IS - 5 N2 - This study aims to determine the effectiveness of paliperidone extended release (ER) on cognitive function in patients with schizophrenia in comparison with risperidone. This was a 12-week, randomized, open-label study on schizophrenia patients who were receiving risperidone. The patients were randomized to a risperidone-continuation group or a paliperidone-switch group. The primary outcome measure was neurocognitive function, which was measured using a computerized battery. Secondary efficacy measures included the Positive and Negative Syndrome Scale, Social and Occupational Functioning Scale, and Calgary Depression Scale for Schizophrenia. In total, 58 patients participated in this trial. Improvements in recall after an interference phase in the verbal learning test were significantly greater in the paliperidone-switch than in the risperidone-continuation group. No significant differences in changes were observed in the other six neurocognitive domains measured. Improvements in the Social and Occupational Functioning Scale were significantly greater in the paliperidone ER-switch group than in the risperidone-continuation group. In other efficacy outcome measures, no significant differences were observed between the two drugs. Paliperidone ER had a side-effect profile similar to that of risperidone, including metabolic problems and prolactin-related adverse events. In conclusion, switching from risperidone to paliperidone ER may lead to additional cognitive and social functional improvements. SN - 1473-5857 UR - https://www.unboundmedicine.com/medline/citation/22809972/Paliperidone_ER_versus_risperidone_for_neurocognitive_function_in_patients_with_schizophrenia:_a_randomized_open_label_controlled_trial_ L2 - https://doi.org/10.1097/YIC.0b013e328356acad DB - PRIME DP - Unbound Medicine ER -